In This Article:
-
Net Product Sales: $5.6 million for Ohtuvayre in the third quarter.
-
Cost of Goods Sold: $500,000 for the quarter ended September 30, 2024.
-
Research and Development Costs: $10.6 million for the quarter, up from $3 million in Q3 2023.
-
Selling, General and Administrative Expenses: $35.2 million for the quarter, compared to $13.4 million in Q3 2023.
-
Net Loss After Tax: $43 million for the quarter, compared to $14.7 million in Q3 2023.
-
Loss Per Share: $0.07 per ordinary share or $0.53 per ADS for the quarter.
-
Cash and Equivalents: $336 million as of September 30, 2024.
Release Date: November 04, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Verona Pharma PLC (NASDAQ:VRNA) successfully launched Ohtuvayre in the US for COPD treatment, achieving net product sales of $5.6 million in just seven weeks.
-
Over 5,000 Ohtuvayre prescriptions were filled within 12 weeks, with more than 2,200 unique healthcare providers prescribing the medication.
-
Ohtuvayre is being prescribed across a broad range of COPD patients, including those on single, dual, and triple therapy, indicating its wide acceptance and potential impact.
-
The company initiated two new Phase II clinical programs, expanding its pipeline and potential future offerings.
-
Verona Pharma PLC (NASDAQ:VRNA) maintains a strong financial position with $336 million in cash and equivalents, providing a runway through at least the end of 2026.
Negative Points
-
The company reported a net loss of $43 million for the third quarter, a significant increase from the $14.7 million loss in the same period in 2023.
-
Research and development costs rose to $10.6 million, driven by increased clinical trial expenses, impacting overall financial performance.
-
Selling, general, and administrative expenses increased substantially to $35.2 million, reflecting higher people-related costs and marketing expenses.
-
Despite the strong launch, Verona Pharma PLC (NASDAQ:VRNA) did not provide specific guidance for the fourth quarter, creating uncertainty about future financial performance.
-
The commercialization of Ohtuvayre faces potential competition from other COPD treatments, such as Dupixent, which could impact market penetration.
Q & A Highlights
Q: Does the October net sales exceeding Q3 indicate a run rate of at least $17 million for the fourth quarter? Are there any factors like holiday periods or patient dropouts that could affect this? A: We are not providing specific guidance for Q4, but we don't foresee any slowdown in patient numbers or interest. We expect the acceleration in Ohtuvayre's use to continue, driven by strong demand and positive feedback from physicians and patients. - David Zaccardelli, CEO